百特国际业绩不及预期股价大跌15%，医疗设备板块承压

Core Viewpoint - Baxter International (BAX.US) experienced a significant stock decline on February 12, 2026, due to its Q4 2025 earnings report and FY 2026 profit guidance falling short of market expectations [1] Financial Performance - For Q4 2025, the adjusted earnings per share (EPS) was $0.44, which was considerably below analyst expectations. However, the quarterly revenue reached $2.97 billion, exceeding market forecasts. The notable decline in profitability raised concerns among investors [2] - The company projected an adjusted EPS range of $1.85 to $2.05 for FY 2026, which is significantly lower than the consensus forecast from analysts. This guidance indicates potential cost pressures or insufficient growth momentum [3] - The financial report indicated a net loss of $2.01 per share for continuing operations under GAAP, which included a goodwill impairment charge of $485 million related to frontline care business and a valuation allowance of $330 million for U.S. deferred tax assets. These one-time charges severely impacted the net profit for the period [4] Stock Performance - Following the disappointing earnings report, Baxter International's stock price plummeted by 15.00% during intraday trading on February 12, closing at $18.93, with a trading volume of $374 million and a turnover rate of 3.76%. On the same day, the overall U.S. medical device sector declined by 3.59%, reflecting shared pressures within the industry [5]